DE60130675D1 - Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose - Google Patents
Selektive agonisten des ep4 rezeptors für die behandlung von osteoporoseInfo
- Publication number
- DE60130675D1 DE60130675D1 DE60130675T DE60130675T DE60130675D1 DE 60130675 D1 DE60130675 D1 DE 60130675D1 DE 60130675 T DE60130675 T DE 60130675T DE 60130675 T DE60130675 T DE 60130675T DE 60130675 D1 DE60130675 D1 DE 60130675D1
- Authority
- DE
- Germany
- Prior art keywords
- osteoporosis
- receptor
- treatment
- selective agonists
- agonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25327500P | 2000-11-27 | 2000-11-27 | |
US253275P | 2000-11-27 | ||
PCT/IB2001/002073 WO2002042268A2 (en) | 2000-11-27 | 2001-11-05 | Ep4 receptor selective agonists in the treatment of osteoporosis |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60130675D1 true DE60130675D1 (de) | 2007-11-08 |
DE60130675T2 DE60130675T2 (de) | 2008-01-24 |
Family
ID=22959588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60130675T Expired - Fee Related DE60130675T2 (de) | 2000-11-27 | 2001-11-05 | Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose |
Country Status (41)
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2429850C (en) * | 2000-11-27 | 2008-12-30 | Pfizer Products Inc. | Ep4 receptor selective agonists in the treatment of osteoporosis |
KR20040015364A (ko) * | 2001-07-16 | 2004-02-18 | 에프. 호프만-라 로슈 아게 | Ep4 수용체 작용물질로서의 프로스타글란딘 유사체 |
BR0211167A (pt) * | 2001-07-16 | 2004-08-10 | Hoffmann La Roche | Derivados de 2-pirrolidona como agonistas de prostanóides |
MXPA04000757A (es) | 2001-07-23 | 2004-07-08 | Ono Pharmaceutical Co | Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo. |
US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
JP4547912B2 (ja) | 2002-03-05 | 2010-09-22 | 小野薬品工業株式会社 | 8−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤 |
JP2005531516A (ja) * | 2002-03-18 | 2005-10-20 | ファイザー・プロダクツ・インク | 選択的ep4受容体アゴニストによる治療方法 |
WO2003077908A1 (en) * | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
EP1513589B1 (de) | 2002-06-06 | 2010-11-10 | Merck Frosst Canada Ltd. | 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom |
JP2005534653A (ja) * | 2002-06-06 | 2005-11-17 | メルク フロスト カナダ アンド カンパニー | 眼及び骨疾患の治療に於いてep4受容体作動薬として使用するための1,5−二置換イミダゾリジン−2−オン誘導体 |
EP1556347A4 (de) * | 2002-06-10 | 2006-08-09 | Applied Research Systems | Gamma-lactame als prostaglandinagonisten und deren verwendung |
GB0219143D0 (en) * | 2002-08-16 | 2002-09-25 | Univ Leicester | Modified tailed oligonucleotides |
JP4497320B2 (ja) | 2002-10-10 | 2010-07-07 | 小野薬品工業株式会社 | 内因性修復因子産生促進剤 |
WO2004037813A1 (en) * | 2002-10-25 | 2004-05-06 | Merck Frosst Canada & Co. | Pyrrolidin-2-on derivatives as ep4 receptor agonists |
US7528163B2 (en) | 2002-11-08 | 2009-05-05 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7053085B2 (en) * | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
CA2511255C (en) * | 2003-01-10 | 2009-04-07 | F. Hoffmann-La Roche Ag | 2-piperidone derivatives as prostaglandin agonists |
WO2004065365A1 (ja) * | 2003-01-21 | 2004-08-05 | Ono Pharmaceutical Co., Ltd. | 8−アザプロスタグランジン誘導体およびその医薬用途 |
JP4662926B2 (ja) | 2003-03-03 | 2011-03-30 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγ−ラクタム誘導体 |
US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
WO2005012232A2 (en) | 2003-07-18 | 2005-02-10 | Applied Research Systems Ars Holding N.V. | Hydrazide derivatives as prostaglandin receptors modulators |
US7034051B2 (en) * | 2003-08-28 | 2006-04-25 | Adolor Corporation | Fused bicyclic carboxamide derivatives and methods of their use |
US7576122B2 (en) | 2003-09-02 | 2009-08-18 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
CN1845904A (zh) | 2003-09-04 | 2006-10-11 | 默克公司 | 用于治疗高眼压的眼用组合物 |
JP2007504236A (ja) | 2003-09-04 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼用組成物 |
WO2005027931A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
BRPI0417621A (pt) * | 2003-12-17 | 2007-04-10 | Pfizer Prod Inc | terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea |
US7169807B2 (en) * | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
AU2005274972A1 (en) | 2004-07-20 | 2006-02-23 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
WO2006043655A1 (ja) | 2004-10-22 | 2006-04-27 | Ono Pharmaceutical Co., Ltd. | 吸入用医薬組成物 |
AU2005299473B2 (en) * | 2004-10-26 | 2012-06-28 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin EP4 agonists |
WO2006052630A1 (en) * | 2004-11-04 | 2006-05-18 | Allergan, Inc. | Therapeutic substituted piperidone compounds |
WO2006052893A2 (en) | 2004-11-08 | 2006-05-18 | Allergan, Inc. | Substituted pyrrolidone compounds as ep4 agonists |
US7101906B2 (en) * | 2004-11-16 | 2006-09-05 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
US7183324B2 (en) | 2004-11-23 | 2007-02-27 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
AU2006209543B2 (en) * | 2005-01-27 | 2009-04-30 | Asahi Kasei Pharma Corporation | Six-membered heterocyclic compound and the use thereof |
US7772392B2 (en) | 2005-05-06 | 2010-08-10 | Allergan, Inc. | Therapeutic substituted β-lactams |
JP5254007B2 (ja) * | 2005-05-06 | 2013-08-07 | アラーガン インコーポレイテッド | 置換β−ラクタム及び医薬におけるその使用 |
US7893107B2 (en) | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
KR100598678B1 (ko) * | 2006-02-15 | 2006-07-19 | (주)아이앤씨 | 수직형 대형 폐기물 파쇄기 |
US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
US9394520B2 (en) | 2006-12-08 | 2016-07-19 | University Of Rochester | Expansion of hematopoietic stem cells |
EP2548559A1 (de) | 2006-12-18 | 2013-01-23 | Allergan, Inc. | Verfahren und Zusammensetzungen zur Behandlung von Magendarm-Erkrankungen |
AU2008246579A1 (en) | 2007-05-08 | 2008-11-13 | National University Corporation, Hamamatsu University School Of Medicine | Cytotoxic T cell activator comprising EP4 agonist |
ES2395875T3 (es) * | 2007-05-23 | 2013-02-15 | Allergan, Inc. | Lactamas cíclicas para el tratamiento del glaucoma o de la presión intraocular elevada |
US8063033B2 (en) * | 2008-01-18 | 2011-11-22 | Allergan, Inc. | Therapeutic beta-lactams |
US8202855B2 (en) | 2008-03-04 | 2012-06-19 | Allergan, Inc | Substituted beta-lactams |
US7705001B2 (en) * | 2008-03-18 | 2010-04-27 | Allergan, Inc | Therapeutic substituted gamma lactams |
JP5536773B2 (ja) * | 2008-08-14 | 2014-07-02 | ベータ・ファーマ・カナダ・インコーポレイテッド | Ep4受容体アンタゴニストとしてのヘテロ環式アミド誘導体 |
WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
KR20120093955A (ko) | 2009-10-14 | 2012-08-23 | 젬머스 파마 인코포레이티드 | 바이러스 감염에 대한 병용 요법 치료 |
WO2011111714A1 (ja) * | 2010-03-08 | 2011-09-15 | 科研製薬株式会社 | 新規なep4アゴニスト |
CA2738045C (en) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
EP2397141A1 (de) * | 2010-06-16 | 2011-12-21 | LEK Pharmaceuticals d.d. | Verfahren zur Synthese von Beta-Aminosäuren und Derivaten daraus |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
AU2012217630A1 (en) | 2011-02-17 | 2013-09-05 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2678022A2 (de) | 2011-02-23 | 2014-01-01 | Allergan, Inc. | Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe |
WO2013123272A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2814526B1 (de) | 2012-02-16 | 2016-11-02 | Allergan, Inc. | Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe |
EP2814482A1 (de) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe |
WO2013123275A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
CA2879506C (en) | 2012-07-19 | 2020-10-27 | Cayman Chemical Company, Inc. | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions |
ES2733998T3 (es) | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
CA2903314C (en) | 2013-03-15 | 2023-02-14 | Cayman Chemical Company, Inc. | Methods of synthesizing a difluorolactam analog |
EA201591793A1 (ru) * | 2013-03-15 | 2016-01-29 | Кайман Кемикал Компани, Инк. | Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний |
EP3021879A2 (de) | 2013-07-19 | 2016-05-25 | Cayman Chemical Company, Incorporated | Verfahren, systeme und zusammensetzungen zur förderung der knochenwachstums |
IL280864B2 (en) | 2013-08-09 | 2024-03-01 | Ardelyx Inc | Compounds and methods for inhibiting phosphate transport |
WO2015056504A1 (ja) | 2013-10-15 | 2015-04-23 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
KR20170010059A (ko) | 2014-06-06 | 2017-01-25 | 알러간, 인코포레이티드 | 치료적 화합물로서 신규한 ep4 작용제 |
US9540357B1 (en) | 2014-07-31 | 2017-01-10 | Allergan, Inc. | 15-aryl prostaglandins as EP4 agonists, and methods of use thereof |
JP7174982B2 (ja) | 2015-06-12 | 2022-11-18 | サイモン フレイザー ユニヴァーシティー | アミド連結ep4アゴニスト-ビスホスホネート化合物およびその使用 |
CN107011377B (zh) * | 2017-05-03 | 2019-02-26 | 南通书创药业科技有限公司 | 一种β-羰基磷酸酯的制备方法 |
EP3733665B1 (de) * | 2017-12-25 | 2022-09-28 | Asahi Kasei Pharma Corporation | 2-oxo-1,3,4-thiadiazinan-3-yl-teil enthaltende verbindungen mit ep4-rezeptor-agonistischer aktivität |
WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1158163A (en) | 1966-06-15 | 1969-07-16 | Berk Ltd | Improvements in or relating to Polymer Compositions |
ZA72645B (en) * | 1971-03-05 | 1972-11-29 | Upjohn Co | Prostaglandin analogs |
DE2346706A1 (de) * | 1973-09-17 | 1975-04-03 | Hoechst Ag | Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung |
US3975399A (en) | 1974-08-06 | 1976-08-17 | E. I. Du Pont De Nemours And Company | 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones |
US4113873A (en) | 1975-04-26 | 1978-09-12 | Tanabe Seiyaku Co. Ltd. | 8-azaprostanoic acid derivatives |
NL7604330A (nl) | 1975-04-28 | 1976-11-01 | Syntex Inc | Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten. |
DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
IL49325A (en) | 1976-03-31 | 1979-11-30 | Labaz | 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them |
DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
CA1077948A (en) * | 1976-08-06 | 1980-05-20 | Albin J. Nelson | 1,-5 disubstituted-2-pyrrolidones and processes for their production |
US4177346A (en) * | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
US4320136A (en) | 1980-08-11 | 1982-03-16 | E. I. Du Pont De Nemours And Company | 8-Aza-16,16-difluoroprostanoids |
US4456613A (en) | 1982-12-27 | 1984-06-26 | E. I. Du Pont De Nemours And Company | 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof |
TW288010B (de) | 1992-03-05 | 1996-10-11 | Pfizer | |
SE9302334D0 (sv) | 1993-07-06 | 1993-07-06 | Ab Astra | New compounds |
ZA944647B (en) | 1993-07-06 | 1995-01-06 | Astra Ab | Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives |
US5955481A (en) | 1994-03-28 | 1999-09-21 | Nissan Chemical Industries, Ltd. | Pyridine type thiazolidines |
TW420669B (en) | 1994-03-28 | 2001-02-01 | Nissan Chemical Ind Ltd | Pyridine type thiazolidines |
US5703108A (en) * | 1996-02-28 | 1997-12-30 | Pfizer Inc. | Bone deposition by certain prostaglandin agonists |
WO2000021542A1 (en) * | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Methods for stimulating bone formation |
CA2346038A1 (en) | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Methods for inhibiting bone resorption |
AU1293101A (en) * | 1999-12-22 | 2001-07-03 | Pfizer Products Inc. | Ep4 receptor selective agonists in the treatment of osteoporosis |
DK1132086T3 (da) * | 2000-01-31 | 2006-08-28 | Pfizer Prod Inc | Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt |
US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
CA2429850C (en) * | 2000-11-27 | 2008-12-30 | Pfizer Products Inc. | Ep4 receptor selective agonists in the treatment of osteoporosis |
US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
-
2001
- 2001-11-05 CA CA002429850A patent/CA2429850C/en not_active Expired - Fee Related
- 2001-11-05 HU HU0400807A patent/HUP0400807A2/hu unknown
- 2001-11-05 EA EA200300379A patent/EA200300379A1/ru unknown
- 2001-11-05 WO PCT/IB2001/002073 patent/WO2002042268A2/en active IP Right Grant
- 2001-11-05 OA OA1200300141A patent/OA12533A/en unknown
- 2001-11-05 SK SK556-2003A patent/SK5562003A3/sk not_active Application Discontinuation
- 2001-11-05 MX MXPA03004623A patent/MXPA03004623A/es active IP Right Grant
- 2001-11-05 CZ CZ20031257A patent/CZ20031257A3/cs unknown
- 2001-11-05 NZ NZ525164A patent/NZ525164A/en unknown
- 2001-11-05 CN CNA018194877A patent/CN1476429A/zh active Pending
- 2001-11-05 SI SI200130776T patent/SI1339678T1/sl unknown
- 2001-11-05 DE DE60130675T patent/DE60130675T2/de not_active Expired - Fee Related
- 2001-11-05 AU AU2002210848A patent/AU2002210848A1/en not_active Abandoned
- 2001-11-05 KR KR10-2003-7007109A patent/KR20030053063A/ko not_active Application Discontinuation
- 2001-11-05 EP EP01978757A patent/EP1339678B1/de not_active Expired - Lifetime
- 2001-11-05 PT PT01978757T patent/PT1339678E/pt unknown
- 2001-11-05 ES ES01978757T patent/ES2291361T3/es not_active Expired - Lifetime
- 2001-11-05 IL IL15536801A patent/IL155368A0/xx unknown
- 2001-11-05 PL PL01362030A patent/PL362030A1/xx not_active Application Discontinuation
- 2001-11-05 JP JP2002544404A patent/JP3984164B2/ja not_active Expired - Lifetime
- 2001-11-05 BR BR0115687-0A patent/BR0115687A/pt not_active Withdrawn
- 2001-11-05 DK DK01978757T patent/DK1339678T3/da active
- 2001-11-05 EE EEP200300246A patent/EE200300246A/xx unknown
- 2001-11-05 AT AT01978757T patent/ATE374182T1/de not_active IP Right Cessation
- 2001-11-21 US US09/990,556 patent/US6552067B2/en not_active Expired - Fee Related
- 2001-11-23 UY UY27038A patent/UY27038A1/es not_active Application Discontinuation
- 2001-11-23 HN HN2001000266A patent/HN2001000266A/es unknown
- 2001-11-26 AR ARP010105489A patent/AR035074A1/es unknown
- 2001-11-26 TW TW093115078A patent/TW200424170A/zh unknown
- 2001-11-26 SV SV2001000746A patent/SV2003000746A/es unknown
- 2001-11-26 TN TNTNSN01166A patent/TNSN01166A1/fr unknown
- 2001-11-26 PE PE2001001180A patent/PE20020637A1/es not_active Application Discontinuation
- 2001-11-27 PA PA20018533901A patent/PA8533901A1/es unknown
- 2001-11-27 GT GT200100238AK patent/GT200100238AA/es unknown
- 2001-11-27 GT GT200100238A patent/GT200100238A/es unknown
-
2002
- 2002-12-20 US US10/326,366 patent/US6747054B2/en not_active Expired - Fee Related
-
2003
- 2003-04-03 BG BG107697A patent/BG107697A/xx unknown
- 2003-04-10 ZA ZA200302803A patent/ZA200302803B/en unknown
- 2003-04-10 IS IS6775A patent/IS6775A/is unknown
- 2003-05-13 MA MA27159A patent/MA26961A1/fr unknown
- 2003-05-26 NO NO20032360A patent/NO20032360L/no not_active Application Discontinuation
- 2003-05-27 EC EC2003004623A patent/ECSP034623A/es unknown
- 2003-09-23 US US10/668,633 patent/US7192979B2/en not_active Expired - Fee Related
-
2007
- 2007-05-11 JP JP2007127062A patent/JP2007197467A/ja active Pending
- 2007-11-06 CY CY20071101420T patent/CY1106976T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE374182T1 (de) | Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose | |
ATE250575T1 (de) | Ep4 rezeptor selektive agonisten zur behandlung der osteoporose | |
ATE266655T1 (de) | Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit | |
ATE312117T1 (de) | Verbindungen für die behandlung von ischämie | |
ATE345331T1 (de) | Verbindungen verwendbar für die behandlung von entzündungskrankheiten | |
DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
DE60236218D1 (de) | CCR5 Antagonisten verwendbar für die Behandlung von Aids | |
DE60022692D1 (de) | (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen | |
DE50011178D1 (de) | Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen | |
DE60032905D1 (de) | Selektive iglur5 rezeptorantagonisten zur behandlung der migräne | |
DE60239558D1 (de) | Kombinationen für die behandlung von immun-entzündlichen erkrankungen | |
ATE422498T1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
IT1319240B1 (it) | Procedimento per la oligomerizzazione selettiva dell'etilene. | |
DE60031790D1 (de) | Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen | |
DE60127712D1 (de) | Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen | |
DE60125597D1 (de) | Vorrichtung für die Dienstleistungsvermittlung | |
DE60133596D1 (de) | S-Methyl-Dihydro-Ziprasidone für die Behandlung von Schizophrenie | |
ATE277924T1 (de) | Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression | |
DE60006363D1 (de) | Aminoacylaroylpyrrole für die behandlung des neuropathischen schmerzes | |
ATE357441T1 (de) | Substituierte 2-pyrrolidin-2-yl-1h-indol- derivative für die behandlung von migräne | |
IT1316554B1 (it) | Dispositivo per il trattamento di rifiuti umidi. | |
ATE271946T1 (de) | Ausziehvorrichtung für pfannenspülsteine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |